Current issues and future directions of oncolytic adenoviruses.
about
MicroRNA-regulated viral vectors for gene therapyMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesMesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunitiesAdenovirus vectors for gene therapy, vaccination and cancer gene therapyThe sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapiesDevelopment of a novel efficient method to construct an adenovirus library displaying random peptides on the fiber knob.Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors.Recent advances in genetic modification of adenovirus vectors for cancer treatmentChemoselective attachment of small molecule effector functionality to human adenoviruses facilitates gene delivery to cancer cells.Replication and virus-induced transcriptome of HAdV-5 in normal host cells versus cancer cells--differences of relevance for adenoviral oncolysis.Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.Molecular characterization of a lizard adenovirus reveals the first atadenovirus with two fiber genes and the first adenovirus with either one short or three long fibers per pentonRedesigning human 2'-deoxycytidine kinase enantioselectivity for L-nucleoside analogues as reporters in positron emission tomographyInfectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted libraryMicroRNA-mediated suppression of oncolytic adenovirus replication in human liverStructure, function and dynamics in adenovirus maturation.Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.Adenoviruses induce autophagy to promote virus replication and oncolysis.IL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cellsChapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer.Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancerLate-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells.Immunotherapy treatments for small-cell lung cancer: past, present and future.Novel therapeutic approaches for small cell lung cancer: the future has arrivedGeneration of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy.CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer.Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses.A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein.A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence.Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model
P2860
Q26745822-9075D40A-31E9-4960-854A-EB8648E494BBQ26752807-0EBDDFCC-C893-488B-B405-AD8FBB72C0FCQ26799013-A98CAD25-95E2-4BBC-8F4C-47FC79BEA940Q27001601-D18E9808-FF43-4F2E-BF14-F99ED1EE59C2Q27023157-62CDEABB-E516-4CC1-9904-255E29B6C93CQ31146926-F5BB1F92-CE1C-4545-9E61-D6175CC79F16Q33560685-C446DBC9-34A9-42EE-88A2-787A206B6A6FQ33738828-3D3A7739-7155-4FCA-8318-7760B5B6F64BQ33862005-C8D5A273-5D26-421D-A3C4-6D43B7A90201Q34091152-0D1C8D85-2368-433C-AB15-BE6552917BFFQ34146469-ECEC7851-1BA2-45FB-AFEC-791F213BE368Q34163338-CF91CCE3-D073-46AB-B4F8-23ABE2FE6B05Q34261815-6D6C6E8E-2398-4CB7-8A70-2D3B1EE44DE4Q34361054-E8639E75-D5E3-49DF-80D8-7041E2C55974Q34432734-10216744-0A6B-4AA8-BF96-70AB8B862501Q34563212-75E23AE1-0260-41F1-91B6-51482E9C27DCQ34580873-350FE4B4-5D95-48BF-97EB-7134F28F3E8AQ34781681-D9A3645F-9E16-4870-BC8A-589939FFC1ECQ35040642-AA6139E3-6287-4AC3-A9A0-0BA4DEC94758Q35126751-DC49970E-C520-4F0F-8B11-7E7F7AC959B0Q35142325-E749E3A0-8F86-466D-B0C0-FC747F21227FQ35156188-F560C815-21CC-411E-8EDC-4A26CD69B340Q35181099-6C5B41C1-7A97-43C7-BBC5-7D4E99B53773Q35226101-C3D6E4E2-33AD-4176-9A9C-59A269B187C8Q35238261-8D7736C3-D353-4611-802C-2B40489DE702Q35563005-E53C7B03-90A1-477B-922A-9FC65069B5CBQ35618835-D8253571-316E-48E5-8D56-11ECBB347657Q35665175-1AFCEE98-B1BC-4999-B1B7-074281B4408BQ35742497-84DC1AD1-EAAF-454E-B600-514637EF7976Q35904003-EBBE1AAF-FE44-43D3-BA76-17DEBF806363Q36084288-891FA6DA-B2F8-4705-B48D-4F6152DA80DCQ36306398-D02BF39A-E0BB-47E3-8224-413E78A2D822Q36406924-289D9786-4837-440B-9277-D0ED3248545FQ36422224-504779B9-DC0E-4D45-B5F3-E2D1C3B0E507Q36544244-EEB7BA4B-AB35-4CBC-96B1-D9B27E3762F4Q36664240-175B701C-0D50-474D-BCEB-4FEBBB41FA67Q36976226-990E29AA-421B-4FB6-B3BE-60FD92216E40Q36984452-D47F8129-70F0-4326-9BD3-25A39358EF4CQ37152107-3B871278-2B96-436A-A96C-D4CCDD39CF22Q37185117-E4BE71C8-06BC-49AC-8483-6A207D2AF77F
P2860
Current issues and future directions of oncolytic adenoviruses.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Current issues and future directions of oncolytic adenoviruses.
@ast
Current issues and future directions of oncolytic adenoviruses.
@en
type
label
Current issues and future directions of oncolytic adenoviruses.
@ast
Current issues and future directions of oncolytic adenoviruses.
@en
prefLabel
Current issues and future directions of oncolytic adenoviruses.
@ast
Current issues and future directions of oncolytic adenoviruses.
@en
P2860
P356
P1433
P1476
Current issues and future directions of oncolytic adenoviruses.
@en
P2093
Masato Yamamoto
P2860
P304
P356
10.1038/MT.2009.266
P577
2009-11-24T00:00:00Z